Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma reported strong standalone performance for FY26 with profit after tax of Rs 24,148 million, up 38.2% from Rs 17,468 million in FY25, driven by higher other income and controlled costs. Consolidated revenue grew 6.4% to Rs 333,847 million, but consolidated PAT was flat at Rs 35,030 million vs Rs 34,836 million. The company completed a Rs 8,000 million share buyback in May 2026. Auditors issued unmodified opinions on both standalone and consolidated results. Exceptional items of Rs 173.8 million (standalone) and Rs 653.3 million (consolidated) relate to increased employee liabilities from new labour codes.
Strong standalone earnings growth with 38% PAT increase is positive for the stock. However, flat consolidated PAT despite revenue growth suggests margin pressures at the group level. The clean audit opinion and completed buyback provide investor comfort.